| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ARTICLES |
Research Center for Endocrinology and Metabolism, Departments of Internal Medicine (V.W., K.W., J.S., C.O., J.-O.J.) and Pathology (M.H.), Sahlgrenska University Hospital, SE-413 45 Gothenburg, Sweden; and Basel Institute for Immunology (M.K.), CH-4005 Basel, Switzerland
Address all correspondence and requests for reprints to: V. Wallenius, M.D., Ph.D., Research Center for Endocrinology and Metabolism, Gröna Stråket 8, SE-413 45 Gothenburg, Sweden. E-mail: ville.wallenius{at}medic.gu.se
The liver size in adult mammals is tightly regulated in relation to
body weight, but the hormonal control of this is largely unknown. We
investigated the roles of interleukin-6 (IL-6) and tumor necrosis
factor (TNF) receptor-1 in the regulation of intact liver weight in
adult mice. The relative liver wet and dry weights of older adult (5-
to 10-month-old) IL-6 knockout (IL-6-/-) mice
were decreased by 2228%, and total contents of DNA and protein were
decreased compared with those in age-matched wild-type mice. Weights of
other visceral organs were unaffected. Older adult (6- to 8-month-old)
TNF receptor-1 knockout (TNFR1-/-) mice
displayed decreased relative liver weight. Treatment with a single
injection of IL-6 increased liver wet and dry weights in
IL-6-/- and wild-type mice, but not
TNFR1-/- mice. Treatment with TNF
enhanced
liver weight and DNA synthesis of nonparenchymal liver cells at 24
h in wild-type, but not IL-6-/-, mice. At
48 h, TNF
induced DNA synthesis in nonparenchymal cells and
hepatocytes of both wild-type and IL-6-/-
mice. In conclusion, TNF receptor-1 stimulation and IL-6 production are
both necessary for normal liver weight gain in older adult mice. The
results of TNF
and IL-6 treatment further indicate that the effects
of TNF receptor-1 and IL-6 depend on each other for full stimulation of
liver growth.
This article has been cited by other articles:
![]() |
C. Porta, M. De Amici, S. Quaglini, C. Paglino, F. Tagliani, A. Boncimino, R. Moratti, and G. R. Corazza Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma Ann. Onc., February 1, 2008; 19(2): 353 - 358. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. M. Argast, J. S. Campbell, J. T. Brooling, and N. Fausto Epidermal Growth Factor Receptor Transactivation Mediates Tumor Necrosis Factor-induced Hepatocyte Replication J. Biol. Chem., August 13, 2004; 279(33): 34530 - 34536. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Stenlof, I. Wernstedt, T. Fjallman, V. Wallenius, K. Wallenius, and J.-O. Jansson Interleukin-6 Levels in the Central Nervous System Are Negatively Correlated with Fat Mass in Overweight/Obese Subjects J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4379 - 4383. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Torbenson, S. Q. Yang, H. Z. Liu, J. Huang, W. Gage, and A. M. Diehl STAT-3 Overexpression and p21 Up-Regulation Accompany Impaired Regeneration of Fatty Livers Am. J. Pathol., July 1, 2002; 161(1): 155 - 161. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |